Amneal Pharmaceuticals Inc. (AMRX) kicked off the year with a bang, generating record levels of revenue in the first quarter. With its business segments firing on all cylinders, the company is poised for 6.7% to 10.8% revenue growth in 2024.
This global pharmaceutical company develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, biosimilars and specialty branded pharmaceuticals. It has three reportable segments - Generics, Specialty, and AvKARE.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com